Dr. Salpeter has deep experience in developing and bringing new biotechnologies to market. He previously served as Co-Founder and CTO at Curesponse, a precision cancer medicine company. Prior to that he was Chief Scientist and VP Business Development at Sight Diagnostics. Dr. Salpeter holds a Ph.D in Biochemistry from the Hebrew University and performed post-doctoral studies at the Institute for Drug Research, the Hebrew University School of Pharmacy.

Dr. Granot is a world recognized expert in the field of neutrophil biology. Previously he identified the neutrophil’s role in anti-cancer activity and discovered the high and low density paradigm of neutrophil regulation suggesting that neutrophils can be repolarized. Recently he has focused his efforts on developing technologies for neutrophil modulation, leading to the founding of Immunyx. Dr. Granot received his Ph.D from the Hebrew University and performed Post-Doctoral work at Memorial Sloan Kettering.

Dr. Fridlender is a clinician with significant knowledge in the function of neutrophils in disease. His original work on neutrophils in cancer led to the discovery of the N1 and N2 phenotypes. His expertise ranges from internal medicine, pulmonology and basic immunological questions. He received his M.D from the Hebrew University Medical School and completed his fellowship at the University of Pennsylvania.